AORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Artivion Inc (AORT) is not a strong buy at this moment for a beginner, long-term investor. While the company has shown strong revenue growth in the latest quarter, the significant drop in net income and EPS, along with bearish technical indicators, suggests caution. The absence of recent positive news, lack of strong trading signals, and neutral sentiment from hedge funds and insiders further support a hold recommendation.
The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 53.129, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock price is currently near the pivot level of 37.4, with resistance at 40.105 and support at 34.695.
Analysts maintain a Buy rating, with a price target of $48, indicating potential upside.
Net income dropped significantly by -114.73% YoY, and EPS decreased by -112.82% YoY. Gross margin slightly declined. Technical indicators are bearish, and there is no recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased to $115.99M (up 19.20% YoY). However, net income dropped to $2.42M (-114.73% YoY), and EPS fell to 0.05 (-112.82% YoY). Gross margin slightly decreased to 63.06% (-0.22% YoY).
Canaccord analyst William Plovanic lowered the price target to $48 from $51 but maintained a Buy rating. The firm highlighted strong Q4 performance, despite a one-time revenue reduction, and expects growth in key product lines like aortic stent grafts and On-X.
